Rephonic
Artwork for Oncology Today

Oncology Today with Dr Neil Love

Dr. Neil Love
Immunotherapy
Breast Cancer
Clinical Trials
Colorectal Cancer
Antibody-Drug Conjugates
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Prostate Cancer
Multiple Myeloma
PARP Inhibitors
Diffuse Large B-Cell Lymphoma
Ovarian Cancer
Circulating Tumor DNA
CAR T-Cell Therapy
BTK Inhibitors
Chemotherapy
Venetoclax
Follicular Lymphoma
Endometrial Cancer
Gastroesophageal Cancer

Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.

PublishesDailyEpisodes501Founded6 years ago
Number of ListenersCategories
ScienceHealth & FitnessMedicine

Listen to this Podcast

Artwork for Oncology Today

Latest Episodes

Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:

• Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)

• Nonmetastatic Disease (10:32)

• Metastatic Androgen Path... more

YouTube

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

• Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic ... more

YouTube

Featuring perspectives from Prof John Seymour, including the following topics:

• Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)

• Venetoclax re-treatment and ongoing trials with acalabrutinib/venetocl... more

YouTube

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

• Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, M... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Recent Guests

Peter Schmid
Professor, Barts Cancer Institute, London
Barts Cancer Institute
Episode: Metastatic Triple-Negative Breast Cancer — Patterns of Care
Melinda Telli
Medical Oncologist, Stanford Cancer Institute
Stanford Cancer Institute
Episode: Metastatic Triple-Negative Breast Cancer — Patterns of Care
Andrea Necchi
Faculty member discussing bladder cancer therapies
IRCCS St. Rafael Hospital
Episode: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Shilpa Gupta
Faculty member discussing bladder cancer therapies
The Tosov Cancer Institute
Episode: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Elizabeth Plemick
Presenter of pre-recorded video case presentations
Fox Chase Cancer Center
Episode: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Thomas Pals
Professor presenting cases
Barts Cancer Institute
Episode: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Terence Friedlander
CME meeting moderator from Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
Episode: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Brian Hill
Faculty from the Cleveland Clinic Taussig Cancer Institute
Cleveland Clinic
Episode: Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances
Stephen Ansell
Faculty from the Mayo Clinic in Rochester
Mayo Clinic
Episode: Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

Host

Neil Love
Host of the program; multiple instances across Oncology Today series

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#112
Hong Kong/Science
Apple Podcasts
#243
United Arab Emirates/Science
Apple Podcasts
#245
Saudi Arabia/Science

Talking Points

Recent interactions between the hosts and their guests.

Gastroesophageal Cancers — Year in Review Series on Relevant New Datasets and Advances
Q: What is the bottom-line takeaway from the recent trials on MSI-H locally advanced disease and dual checkpoint inhibitor therapy?
Dual checkpoint inhibition in MSI-H locally advanced gastric junctional cancers produced high pathologic complete responses and encouraging long-term disease-free survival, suggesting a potential shift toward organ-sparing strategies in selected patients.
AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Q: How early in prostate tumorigenesis does PTEN loss occur, and is it primarily initiating or a driver of progression?
PTEN loss is seen early and tends to be associated more with disease progression than as the initiating event, suggesting it acts as a driver of progression in many cases rather than starting tumorigenesis.
AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Q: Should PTEN testing be routine at MHSPC diagnosis to identify candidates for AKT inhibitor therapy, and how would you prioritize triplet therapy with docetaxel versus ARPI plus AKT inhibitor?
PTEN testing is considered valuable for selecting candidates with PTEN loss; in practice, triplet therapy incorporating AKT inhibition may be favored in PTEN-deficient patients, particularly when aiming for maximal disease control in earlier disease stages, though individual patient factors and regulatory approvals guide decisions.
AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Q: What were the main reasons the Ipatasertib program did not move forward despite positive signals in subsets of patients, and how did pharmacologic differences between Ipatasertib and Capivasertib influence future development?
Reasons included modest magnitude of benefit in some populations and the strategic shift toward agents with more robust and consistent signals; pharmacologic differences between the two agents, along with trial designs, supported moving toward Capivasertib in settings where data were more convincing.
AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Q: Looking back at the I-potential 150 trial, what was the key signal that convinced the field that AKT inhibition is biologically meaningful?
The panel emphasized that consistent signals across trials in PTEN-deficient tumors, showing meaningful progression-free outcomes when AKT inhibition is combined with standard therapy, suggested a true biological effect rather than a random association.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About Oncology Today

What is Oncology Today about and what kind of topics does it cover?

A clinically oriented show featuring medical oncologists and cancer researchers discussing new research, treatment strategies, and practical applications for general oncology practice. Episodes commonly center on hematologic and solid tumor malignancies, with deep dives into frontline versus relapse options, sequencing of therapies, adverse event management, and emerging modalities such as MRD-guided decisions, fixed-duration regimens, and novel agents (including BTK inhibitors, venetoclax-based regimens, HER2-targeted therapies, and cell/immune-based approaches). Guests frequently come from major academic centers and cancer institutes, bringing case-based perspectives, trial context, and real-world considerations to help practicing oncolog... more

Where can I find podcast stats for Oncology Today?

Rephonic provides a wide range of podcast stats for Oncology Today. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to Oncology Today and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does Oncology Today get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for Oncology Today, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for Oncology Today?

Rephonic provides comprehensive predictive audience data for Oncology Today, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does Oncology Today have?

To see how many followers or subscribers Oncology Today has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to Oncology Today?

These podcasts share a similar audience with Oncology Today:

1. Two Onc Docs
2. Research To Practice | Oncology Videos
3. Oncology Brothers: Practice-Changing Cancer Discussions
4. Breast Cancer Update
5. OncLive® On Air

How many episodes of Oncology Today are there?

Oncology Today launched 6 years ago and published 501 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact Oncology Today?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for Oncology Today?

Rephonic pulls ratings and reviews for Oncology Today from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for Oncology Today?

Rephonic provides full transcripts for episodes of Oncology Today. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on Oncology Today?

Recent guests on Oncology Today include:

1. Peter Schmid
2. Melinda Telli
3. Andrea Necchi
4. Shilpa Gupta
5. Elizabeth Plemick
6. Thomas Pals
7. Terence Friedlander
8. Brian Hill

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days